Biopharma/pharma Companion Diagnostics and TDM

HomeResearch TopicsBiopharma/pharma Companion Diagnostics and TDM
Biopharma/pharma Companion Diagnostics and TDM 2016-11-10T19:19:28+00:00

Research overview–therapeutic monitoring of drug effects and toxicity (TDM), companion diagnostics, and stratification of disease state and phenotype.


Characterization of therapeutic antibodies and antibody drug conjugates by MS

Recent advancements in proteomics have led to an increase in biotherapeutic drugs. Monoclonal antibodies (mAbs) and derivatives such as antibody-drug conjugates (ADC) and bispecific antibodies (bsAb), are rapidly growing classes of biotherapeutic drugs. Antibody-drug conjugates (ADCs), a class of cancer therapeutics, deliver potent cytotoxins directly to tumors to minimize systemic toxicity. The complexity of these therapeutics far exceeds that of small molecule drugs, producing significant analytical challenges. The following articles provide an overview of recent advancements in absolute quantitation of protein therapeutics in biological matrices by LC-MS. Articles of note ›

Patient stratification and measuring protein heterogeneity using MS

These papers investigate the potential diagnostic value of different biomarkers in drug development and clinical environments. Using MS-based methods, researchers are finding that protein levels are heritable molecular phenotypes that exhibit considerable variation between individuals, populations and sexes. The potential markers identified through proteomic fingerprinting could serve to stratify and classify diseases in populations. Articles of note ›

Monitoring proteins for TDM using MS

MS is regarded as one of the most important analytical tools in the study of drug metabolism, an essential part of the drug development process and. These papers review the use of MS in drug metabolism and toxicology, highlighting new applications and trends. Articles of note ›